Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients von Vogelmeier, C, Verkindre, C, Cheung, D, Galdiz, J.B, Güçlü, S.Z, Spangenthal, S, Overend, T, Henley, M, Mizutani, G, Zeldin, R.K

Volltext

Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, Phase 3 LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squa... von Goss, G., Lee, K.H., Felip, E., Cobo, M., Syrigos, K., Goker, E., Georgioulias, V., Guclu, S.Z., Isla, D., Min, Y.J., Morabito, A., Dupuis, N., Chand, V.K., Solca, F., Krämer, N., Gibson, N., Ehrnrooth, E., Soria, J.C.

Volltext

What happens when oral tuberculosis is not treated? von Erbaycu, A E, Taymaz, Z, Tuksavul, F, Afrashi, A, Güçlü, S Z

Volltext

1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG F... von Goss, G., Felip, E., Cobo, M., Lu, S., Syrigos, K.N., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Isla, D., Morabito, A., Guclu, S.Z., Min, Y.J., Ardizzoni, A., Gadgeel, S., Love, J., Chand, V., Soria, J-C.

Volltext

A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Follow... von Goss, G., Felip, E., Cobo, M., Lu, S., Syrigos, K.N., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Isla, D., Morabito, A., Guclu, S.Z., Min, Y.J., Ardizzoni, A., Gadgeel, S., Love, J., Chand, V., Soria, J-C.

Volltext